Qiagen Introduces Technology for Customized RNAi Assay Products

Qiagen has introduced FlexiPlate siRNA, product line for fully customized sets of siRNAs for RNA Interference research.

This year's Nobel Prize in Medicine was awarded to Craig C. Mello and Andrew Z. Fire for research in the field of RNAi.

Qiagen's FlexiPlate siRNA is designed to ensure a dimension of flexibility by allowing users to determine not only the exact RNAi assay, but also exactly the amount of siRNAs needed for their individual requirements.

FlexiPlate is designed to allow customers to quantify the number of RNAi assays needed, thereby often leading to the ability to use 7 times as many assays when compared to unquantified offerings, in low throughput RNAi.

The Company claims that, customers can select and order any set of siRNAs interactively via Qiagen's GeneGlobe web portal which hosts the world's largest database of matching siRNA assays for all human and mouse genes as well as the corresponding gene expression assays.

The selected siRNA sets are then delivered in standard 96-well plates, which allow direct processing by customers.

"The new FlexiPlate siRNA product line provides a dramatic step forward for research applying RNAi," said Dr. Bettina Haedrich, Global Product Manager RNAi at Qiagen.

"It expands Qiagen's already broad portfolio of RNAi solutions and capabilities and demonstrates the company's well established and expanding leadership in this field."

"Most researchers know the problem of having too much siRNA or too many siRNAs for their experiments."

"With FlexiPlate siRNAs and GeneGlobe technology, they find now an effective tool which makes their RNA screening more flexible, economical and convenient," Dr. Haedrich added.